Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 3, 2014, Pages 166-176

  Rana, Huma Q ^a   Rainville, Irene R ^a   Vaidya, Anand ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

counselling; genetic testing; inheritance; next generation sequencing; paraganglioma; pheochromocytoma

Indexed keywords

ADULT; CANCER GENETICS; CASE REPORT; CLINICAL FEATURE; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERMLINE MUTATION; HUMAN; PARAGANGLIOMA; PEDIGREE; PHENOTYPE; PHEOCHROMOCYTOMA; REVIEW; ADRENAL GLAND NEOPLASMS; DNA SEQUENCE; FAMILY; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETICS; MALE;

TUMOR MARKER;

ADRENAL GLAND NEOPLASMS; FAMILY; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84899957575     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000059     Document Type: Review

References (97)

1. Jiang S, Dahia PL. Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. Endocrinology 2011; 152:2133-2140.
2. Welander J, Soderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18:R253-R276.
3. Shankavaram U, Fliedner SM, Elkahloun AG, et al. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia (New York, NY) 2013; 15:435-447.
4. Jochmanova I, Yang C, Zhuang Z, Pacak K. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst 2013; 105:1270-1283.
5. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 2012; 44:328-333.
6. Kaelin WG. Von Hippel-Lindau disease. Ann Rev Pathol 2007; 2:145-173.
7. Boedeker CC, Erlic Z, Richard S, et al. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2009; 94:1938-1944.
8. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275.
9. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275:25733-25741.
10. Ong KR, Woodward ER, Killick P, et al. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007; 28:143-149.
11. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459-1466.
12. Neumann HP, Eng C. The approach to the patient with paraganglioma. J Clin Endocrinol Metab 2009; 94:2677-2683.
13. Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 2009; 94:1541-1547.
14. Cascon A, Pita G, Burnichon N, et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab 2009; 94:1701-1705.
15. Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009; 94:2817-2827.
16. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotypephenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 2010; 31:41-51.
17. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292:943-951.
18. Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 2012; 205:1-11.
19. Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 2006; 91:4505-4509.
20. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63:5615-5621.
21. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007; 92:3822-3828.
22. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 2009; 266:19-42.
23. Bickmann JK, Sollfrank S, Schad A, et al. Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: lessons from 3 unrelated cases with an identical germline mutation. J Clin Endocrinol Metab 2014. [Epub ahead of print].
24. Efstathiadou ZA, Sapranidis M, Anagnostis P, Kita MD. Unusual case of Cowdenlike syndrome, neck paraganglioma, and pituitary adenoma. Head Neck 2014; 36:E12-E16.
25. Eng C. Mendelian genetics of rare - and not so rare - cancers. Ann N Y Acad Sci 2010; 1214:70-82.
26. Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 2011; 96:E2063-E2071.
27. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008; 16:79-88.
28. Xekouki P, Stratakis CA. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer 2012; 19:C33-C40.
29. Xekouki P, Pacak K, Almeida M, et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? J Clin Endocrinol Metab 2012; 97:E357-E366.
30. Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010; 19:3011-3020.
31. Wagner AJ, Remillard SP, Zhang YX, et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 2013; 26:289-294.
32. Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol 2013; 37:234-240.
33. Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011; 96:E1472-E1476.
34. Pantaleo MA, Astolfi A, Urbini M, et al. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. Eur J Hum Genet 2014; 22:32-39.
35. van Baars F, Cremers C, van den Broek P, et al. Genetic aspects of nonchromaffin paraganglioma. Hum Genet 1982; 60:305-309.
36. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009; 325:1139-1142.
37. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406-410.
38. Castro-Vega LJ, Buffet A, de Cubas AA, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 2013. [Epub ahead of print]
39. Pacak K, Jochmanova I, Prodanov T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 2013; 31:1690-1698.
40. Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012; 367:922-930.
41. Yang C, Sun MG, Matro J, et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 2013; 121:2563-2566.
42. Buffet A, Smati S, Mansuy L, et al. Mosaicism in HIF2A-related polycythemiaparaganglioma syndrome. J Clin Endocrinol Metab 2014; 99:E369-E373.
43. Lorenzo FR, Yang C, Ng Tang Fui M, et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med 2013; 91:507-512.
44. Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008; 359:2685-2692.
45. Astuti D, Ricketts CJ, Chowdhury R, et al. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer 2011; 18:73-83.
46. Schlisio S, Kenchappa RS, Vredeveld LC, et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Develop 2008; 22:884-893.
47. Yeh IT, Lenci RE, Qin Y, et al. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 2008; 124:279-285.
48. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 2002; 17:548-554.
49. Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus 2010; 28:E8.
50. Friedman JM. Neurofibromatosis 1. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. Gene Reviews. Seattle, WA; 1993-2014. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1109/
51. Bausch B, Borozdin W, Mautner VF, et al. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007; 92:2784-2792.
52. Zinnamosca L, Petramala L, Cotesta D, et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Arch Dermatol Res 2011; 303:317-325.
53. Bausch B, Wellner U, Bausch D, et al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer 2014; 21:17-25.
54. Fishbein L, Merrill S, Fraker DL, et al. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 2013; 20:1444-1450.
55. Santoro M, Melillo RM, Carlomagno F, et al. Molecular biology of the MEN2 gene. J Intern Med 1998; 243:505-508.
56. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005; 15:531-544.
57. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276:1575-1579.
58. Thosani S, Ayala-Ramirez M, Palmer L, et al. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2013; 98:E1813-E1819.
59. Moline J, Eng C. Multiple endocrine neoplasia type 2. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. Gene reviews. Seattle, WA; 1993-2014. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1257/
60. Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005; 257:60-68.
61. Modigliani E, Vasen HM, Raue K, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med 1995; 238:363-367.
62. Ilias I, Pacak K. Diagnosis localization and treatment of pheochromocytoma in MEN 2 syndrome. Endocr Regul 2009; 43:89-93.
63. Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010; 42:229-233.
64. Qin Y, Deng Y, Ricketts CJ, et al. The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. Hum Mol Genet 2014. [Epub ahead of print]
65. Abermil N, Guillaud-Bataille M, Burnichon N, et al. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J Clin Endocrinol Metab 2012; 97:E805-E809.
66. Yao L, Schiavi F, Cascon A, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 2010; 304:2611-2619.
67. Neumann HP, Sullivan M, Winter A, et al. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab 2011; 96:E1279-E1282.
68. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011; 43:663-667.
69. Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 2008; 105:6584-6589.
70. Jimenez RH, Lee JS, Francesconi M, et al. Regulation of gene expression in hepatic cells by the mammalian target of rapamycin (mTOR). PLoS One 2010; 5:e9084.
71. Burnichon N, Cascon A, Schiavi F, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012; 18:2828-2837.
72. Baysal BE, McKay SE, Kim YJ, et al. Genomic imprinting at a boundary element flanking the SDHD locus. Human Mol Genet 2011; 20:4452-4461.
73. Baysal BE. Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochim Biophys Acta 2013; 1827:573-577.
74. Hoekstra AS, Bayley JP. The role of complex II in disease. Biochim Biophys Acta 2013; 1827:543-551.
75. Alston CL, Davison JE, Meloni F, et al. Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet 2012; 49:569-577.
76. Horvath R, Abicht A, Holinski-Feder E, et al. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). J Neurol Neurosurg Psychiatry 2006; 77:74-76.
77. Yeap PM, Tobias ES, Mavraki E, et al. Molecular analysis of pheochromocytoma after maternal transmission of SDHD mutation elucidates mechanism of parent-of-origin effect. J Clin Endocrinol Metab 2011; 96:E2009-E2013.
78. Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paragangliomapheochromocytoma syndromes. Human Pathol 2010; 41:805-814.
79. van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009; 10:764-771.
80. Rattenberry E, Vialard L, Yeung A, et al. A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013; 98:E1248-E1256.
81. McInerney-Leo AM, Marshall MS, Gardiner B, et al. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clin Endocrinol 2014; 80:25-33.
82. Crona J, Delgado Verdugo A, Maharjan R, et al. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab 2013; 98:E1266-E1271.
83. Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005; 37:1038-1040.
84. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genetics Develop 2009; 19:230-236.
85. Aoki Y, Matsubara Y. Ras/MAPK syndromes and childhood hematooncological diseases. Int J Hematol 2013; 97:30-36.
86. Dahia PLM. The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage. J Clin Endocrinol Metab 2013; 98:2679-2681.
87. Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005; 90:2068-2075.
88. Eisenhofer G, Lenders JW, Timmers H, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011; 57:411-420.
89. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL. EVA Investigators. J Clin Endocrinol Metab 2013; 98:E162-E173.
90. Maurice JB, Troke R, Win Z, et al. A comparison of the performance of (6)(8)Ga-DOTATATE PET/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nuclear Med Mol Imaging 2012; 39:1266-1270.
91. Jasperson KW, Kohlmann W, Gammon A, et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer 2013. [Epub ahead of print]
92. Dwight T, Mann K, Benn DE, et al. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 2013; 98:E1103-E1108.
93. Papathomas TG, Gaal J, Corssmit EP, et al. Nonpheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenaserelated PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 2014; 170:1-12.
94. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565-612.
95. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658-5671.
96. Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handbook Clin Neurol 2013; 115:939-955.
97. Pithukpakorn M, Toro JR. Hereditary leiomyomatosis and renal cell cancer. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. Gene Reviews. Seattle, WA; 1993-2014. Available from: http://www.ncbi.nlm. nih.gov/books/NBK1252/